NCT03530553 is a NA clinical trial of Hunt Motivational Scale in Weight Loss, sponsored by Penn Medicine Princeton Health.

Who is sponsoring NCT03530553?

NCT03530553 is sponsored by Penn Medicine Princeton Health.

What drugs are being tested in NCT03530553?

Interventions in NCT03530553: Hunt Motivational Scale.

What condition does NCT03530553 study?

NCT03530553 studies Weight Loss.

Is NCT03530553 still recruiting?

NCT03530553 is currently status unknown. Last updated 21 May 2018.

Last reviewed 2018-05-21 · How we verify

NCT03530553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using the Hunt Motivational Scale to Aid in Weight Loss and Weight Maintenance

Status unknown NA Last updated 21 May 2018

What this trial tests

NA trial testing Hunt Motivational Scale in Weight Loss in 75 participants. Status unknown.

Timeline

11 April 2018

Primary endpoint
11 October 2018

11 October 2018

Quick facts

Lead sponsor	Penn Medicine Princeton Health
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	11 April 2018
Primary completion	11 October 2018
Estimated completion	11 October 2018
Sites	1 location across United States

Drugs / interventions tested

Hunt Motivational Scale

Conditions studied

Weight Loss — all drugs for Weight Loss →

Sponsor

Penn Medicine Princeton Health

Who can join

Eligibility, any sex, with Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we plan to determine the efficacy of the Hunt Motivational Scale as a tool for weight loss compared to standard of care in the Penn Medicine Princeton Health weight management program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Weight Loss

Currently open trials in the same condition.

NCT06811324 — Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults · Phase 2 · recruiting
NCT07223983 — Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) · Phase 1 · recruiting
NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting
NCT06785064 — Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance · NA · recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03530553 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Penn Medicine Princeton Health
Last refreshed: 21 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03530553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing